Azalea Therapeutics: Funding, Investors & Team (Sep 2026)
Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.
Azalea Therapeutics has raised $65.0M across 1 funding round on record, the most recent a Series A of $65.0M announced in Nov 2025.
That round is above the $15M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Azalea Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2025.
Azalea Therapeutics Funding Rounds
Azalea Therapeutics Founders and Leadership Team
Contact details for the Azalea Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Azalea Therapeutics Funding Compared to Other Biotechnology Startups
Azalea Therapeutics' latest round of $65.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Azalea Therapeutics in Biotechnology and Berkeley
Companies Similar to Azalea Therapeutics
Cartography is an oncology company that develops cancer immunotherapies that target novel and highly specific…
Repair Biotechnologies is a biotechnology company developing therapies based on the cholesterol-degrading…
Skeletalis develops precision medicines targeting bone loss to treat osteoporosis and prevent fractures…
Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and…
Excellergy develops portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe…
Curadel Surgical Innovations oversees the complete process of Curadel's FLARE contrast agents for…
Ventuno Biotech is a biotech company that is developing innovative cancer therapies.
T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.
Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the…
Adaptam Therapeutics is at the forefront of next-generation cancer immunotherapies
Treating the seeds of cancer
Nuclide Therapeutics provides radiopharmaceutical medicines that combine nuclear medicine and biotechnology.
Azalea Therapeutics Funding FAQs
What does Azalea Therapeutics do?
Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.
How much funding has Azalea Therapeutics raised?
Azalea Therapeutics has raised $65.0M across 1 round on record. The most recent is a Series A of $65.0M announced in Nov 2025.
When did Azalea Therapeutics last raise funding?
Azalea Therapeutics' most recent funding round on record is a Series A of $65.0M, announced in Nov 2025.
Where is Azalea Therapeutics headquartered?
Azalea Therapeutics is based in Berkeley, United States.
How many employees does Azalea Therapeutics have?
Azalea Therapeutics is in the 11-50 employee band.
How does Azalea Therapeutics' funding compare to other Biotechnology startups?
Azalea Therapeutics' latest round of $65.0M is above the $15M median round size for Biotechnology companies on FundedIQ across 16 tracked companies over the last two years.
About FundedIQ's Azalea Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Azalea Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.